How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 180-page report you will receive 67 tables and 50 figures– all unavailable elsewhere.
The 180-page report provides clear detailed insight into the Hepatits C Therapies market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
The revenue of the Hepatitis C market in 2016 is estimated at $19bn and is expected to grow at a CAGR of 1.7% in the first half of the forecast period. Oral antivirals accounted for the largest share of the market in 2016, this segment generated $18.7bn.
Read on to discover how this definitive report can transform your own research and save you time. The new market assessment benefits research, analysis and planning in seven main ways: • World HCV market revenue to 2027 – discover that industry’s overall sales potential • Two product classes’ revenues to 2027 – investigate categories at world level, finding the most lucrative and promising therapy classes • Eight leading drugs’ revenues to 2027 – find sales predictions for top and emerging products, seeing how agents compete and succeed • 11 national markets in the Americas, Europe and Asia covered, with forecasts to 2027 – discover the best countries for trade expansion • Activities of established, rising and emerging companies – hear about firms’ products, capabilities, advances, collaborations and outlooks • R&D for antiviral medicines – investigate progress in that industry, exploring technological, clinical and commercial opportunities • Analysis of what stimulates and restrains that industry and market – assess challenges, strengths, competition and opportunities, helping you succeed.
There you explore business intelligence with research, opinions and predictions found only in that work.
Trying our investigation now lets you discover trends, opportunities and prospects For treating hepatitis C virus, our report shows you data, trends, opportunities and multilevel sales forecasts. So, avoid missing out. Instead please get that new analysis here now.
Report highlights • 192 pages, 67 tables and 50 figures • Hepatitis C Market Therapies Market Forecast from 2017 to 2027 • This report also breaks down the revenue forecast for the main submarkets: • Oral Antivirals • Interferons
• Analysis of the Oral Antivirals drugs market. Revenue forecasts to 2027 are provided for the following drugs: • Harvoni • Sovaldi • Epclusa • Daklinza
• Analysis of the Interferons drugs market. Revenue forecasts to 2027 are provided for the following drugs: • Pegasys • PegIntron
• Analysis of key players in Hepatitis C Therapeutics • Gilead Sciences • Merck and Co. • Roche • Bristol Myers Squibb • Janssen • Achillion Pharmaceuticals
• Regional Hepatitis C market forecasts from 2017-2027 • US forecast 2017-2027, • China forecast 2017-2027 • Japan forecast 2017-2027 • India forecast 2017-2027 • Germany forecast 2017-2027 • UK forecast 2017-2027 • France forecast 2017-2027 • Brazil Forecast 2017-2027 • Russia Forecast 2017-2027
• Key questions answered • What does the future hold for the Hepatitis C Therapies industry? • Where should you target your business strategy? • What technologies give the most promising candidates for new drugs? • Which disruptive technologies should you invest in? • Which companies should you form strategic alliances with? • Which company is likely to success and why? • What business models should you adopt? • What industry trends should you be aware of? • Which is the company with the highest expected revenue from 2017 to 2027? • Where lie the best geographical opportunities for selling those antivirals? • Why will the HCV drug market expand, and what limits its sales growth? • How will companies overcome challenges in serving regulators, patients and payers?
• Target audience • Leading Hepatitis C companies • Suppliers • Contractors • Technologists • R&D staff • Consultants • Analysts • CEO’s • CIO’s • COO’s • Business development managers • Investors • Governments • Agencies • Industry organisations • Banks
With our study you see how that market can develop and perform, benefiting your reputation for insight and authority.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview
1.1 Overview of the World Market for Hepatitis C Therapies
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by this Analysis
1.5 Who is this Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain
2. Introduction to Hepatitis C Therapies
2.1 A Breif History of Hepatitis C and Treatments
2.2 Genotypes
2.3 Symptoms: Acute and Chronic Hepatitis C
2.4 Diagnosing Hepatitis C: The Asymptomatic Nature
2.5 Risk Factors for Hepatitis C
2.6 Incidence and Prevalence Patterns
2.7 Hepatitis C: Treatment and Prevention
2.8 Antivirals: Inhibiting Virus Replication
2.8.1 Protease Inhibitors
2.8.2 Polymerase Inhibitors
2.8.3 NS5A Replication Complex Inhibitors
2.9 Interferons: Dual Mode of Action
2.9.1 Combination Therapy: Treatment with Interferons and Antivirals
2.9.2 Interferon-Free Regimens
2.10 Hepatitis C and the Need for a Vaccine
3. The World Hepatitis C Therapies Market, 2017-2027
3.1 Hepatitis C Therapies Market, 2015 and 2016
3.2 The Hepatitis C Therapies Market: Revenue Forecast, 2016-2027
3.3 Rising Awareness and Screening: Expanding Treatment Population
3.4 Generic Competition in the Hepatitis C Therapies Market
3.5 Biosimilar Interferons
3.6 Direct-Acting Antivirals (DAAs): A Change in Therapeutic Landscape
7.6.4 Future Outlook: Company Pins Hopes on Launch of Pipeline Therapies
7.7 Leading Hepatitis C Pipeline Companies, 2017
7.8 Gilead Sciences
7.9 Merck & Co.
7.10 AbbVie (Formerly Abbott Laboratories): New Venture into Hepatitis C
7.11 Achillion Pharmaceuticals: Next Target for Acquisition
7.11.1 Achillion and Gilead
7.11.2 Achillion and Janssen
8. Hepatitis C Therapies Market: Industry Trends, 2016-2027
8.1 SWOT Analysis of the World Hepatitis C Therapies and Vaccines Market, 2016-2027
8.1.1 Strengths and Weaknesses in the Hepatitis C Therapies Market, 2016-2027
8.1.1.1 Interferon Therapy Has Drawbacks
8.1.1.2 Genotype 1: A Common but Difficult to Treat Form of Hepatitis C
8.1.2 Opportunities and Threats in the Hepatitis C Therapies Market, 2016-2027
8.1.2.1 Hepatitis Screening and Diagnosis
8.1.2.2 Raising Awareness and Overcoming Social Stigma
8.1.2.3 Personalised Therapy
8.1.2.4 HIV Co-Infection
8.1.2.5 Asia
8.2 STEP Analysis of the World Hepatitis C Therapies and Vaccines Market, 2016-2027
8.2.1 Social Development
8.2.1.1 Social Implications in China
8.2.2 Technological Advances
8.2.3 Economic Pressures
8.2.4 Political Issues
8.3 Hepatitis C Vaccines
8.4 Oral Direct-Acting Antivirals
8.5 Nucleoside and Non-Nucleoside Polymerase Inhibitors
8.6 Combining Protease and Polymerase Inhibitors
8.7 The Need for Ribavirin
8.8 Twelve-Week Treatment Target
8.9 Pharmaceutical Investment in Hepatitis C
8.9.1 Licensing and Partnering Deals
8.9.2 Acquisitions in Hepatitis C
8.9.3 Other Companies of Note for Hepatitis Treatment Developments
9. Conclusions
9.1 State of the Hepatitis C Therapies Market, 2016 and 2017
9.2 Growth in the Hepatitis C Therapies Market, 2016-2027
9.2.1 Rise of Direct-Acting Antivirals in Hepatitis C
9.2.2 Asia as a Hepatitis C Drug Market
9.3 Concluding Remarks
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form
List of Tables
Table 1.1 Submarket Forecasts of Hepatitis C Therapies, 2016-2027
Table 2.1 Global Pattern of Hepatitis C Genotypes and Subtypes, 2016
Table 2.2 Approved Antiviral Subtypes for Hepatitis C, 2016
Table 3.1 Hepatitis C Therapies Market ($mn) by Sector and Market Share (%) 2015
Table 3.2 Hepatitis C Therapies Market ($mn) and Market Share (%) by Sector, 2016
Table 3.3 Hepatitis C Therapies Market: Overall Market Forecast of Currently Approved Drugs and Predicted Approvals ($mn), AGR (%) and CAGR (%), 2016-2027
Table 3.4 Hepatitis C Therapies Market: Revenue Forecasts by Segment ($mn), AGR (%) and CAGR (%), 2016-2027
Table 3.5 Selected Biosimilar Interferon Alpha Therapies Approved in Emerging National Markets, 2016
Table 3.6 Leading Hepatitis C Antivirals: Revenue Shares by Drug ($mn) and Market Share (%), 2016
Rising incidences of viral infection; increasing geriatric population is projected to propel the demand for anti-viral drugs; advancement in anti-viral...
The oligonucleotide synthesis demand has increased as a result of increased government spending, research and development expenses on pharmaceutical and...
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
